WALTHAM, Mass.– Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced today the signing of a definitive agreement for a recapitalization transaction led by Kohlberg & Company, a leading private equity firm with more than 30 years of experience. Trinity has been partnered with Parthenon Capital since early 2018 to rapidly grow its team, capabilities and global footprint. This recapitalization will provide Trinity with a new capital partner with similarly deep experience supporting growth-oriented life sciences companies and will enable the Company to continue its focus on global expansion and offering its life sciences client base innovative new products and services. Trinity’s management team, led by CEO David Fitzhenry, will continue to lead the organization through its ongoing strategic growth.
“We are thrilled to partner with Kohlberg & Co. through our next chapter of growth as we continue to empower the life sciences industry to deliver life-changing therapies to patients,” said David Fitzhenry, CEO, Trinity Life Sciences. “Kohlberg will help us strategically grow. You will see a greater emphasis on optimizing our global reach, introducing technology that our clients can easily leverage into their own current systems, and a continued focus on actionable data that fuels all our innovative products and services.”
“We were looking for a partner that really understood that our biggest asset is our people, and Kohlberg did just that,” said Leslie Orne, Chief Client Officer, Trinity Life Sciences. “As we invest in people, products and technology, it is important we make clear the impact and ripple effect of new opportunities to our employee base. Kohlberg shares our vision of uplifting current and future leaders within Trinity with an eye towards diversity and inclusion. They also understand our intense commitment to providing high-value, integrated technology and services to the life sciences industry and will continue to support our relentless focus on client needs.”
“We are honored to have the opportunity to partner with Trinity and support its accelerating growth, while adhering to its commitment to offer high-value commercialization services to life sciences companies,” said Chris Anderson, Partner of Kohlberg & Co. “Through our industry research we see the tremendous potential the biopharmaceutical industry has in bringing a higher quality of life to the world, and our firm has deep conviction to invest in industry-leading companies that are driven by the same vision and mission. We look forward to contributing our team’s insights and our deep capital base to help extend Trinity’s innovative suite of capabilities that bring life-changing drugs, devices and treatments to the market.”
Trinity will have a new 10-person Board that includes seasoned, gender-diversified, life sciences industry veterans and investment professionals.
“We are thrilled to be partnering with such an impressive and inspirational management team and employee base,” added Matt Jennings, Operating Partner of Kohlberg & Co. and future Chairman of Trinity. “The energy, enthusiasm and vision of Trinity’s management team, coupled with their commitment to a unified, team-oriented and collaborative culture, is unmatched in their industry. We are looking forward to sharing our resources and helping the Company broaden its technology and data-driven services and its global presence in the years to come.”
Jefferies LLC served as lead financial advisor and SVB Leerink served as co-advisor to Trinity in connection with the transaction, and Kirkland & Ellis LLP acted as legal counsel. Centerview Partners LLC served as financial advisor to Kohlberg, and Ropes & Gray LLP acted as its legal counsel. The transaction is expected to close within the next 30 days.
